Up a level |
Journal Article
Gaidzik, V., I, Weber, D., Paschka, P., Krieger, S., Kaumanns, A., Kroenke, J., Kapp-Schwoerer, S., Koehne, C-H, Horst, H-A, Schmidt-Wolf, I. G. H., Held, G., Kuendgen, A., Ringhoffer, M., Goetze, K., Kindler, T., Fiedler, W., Wattad, M., Corbacioglu, A., Bullinger, L., Schlegelberger, B., Thol, F., Heuser, M., Ganser, A., Schlenk, R. F., Doehner, H. and Doehner, K. (2015). DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML): monitoring of minimal residual disease (MRD). A study of the AML Study Group (AMLSG). Oncol. Res. Treat., 38. S. 7 - 8. BASEL: KARGER. ISSN 2296-5262
Hoyer, K., Hablesreiter, R., Inoue, Y., Yoshida, K., Briest, F., Christen, F., Kakiuchi, N., Yoshizato, T., Shiozawa, Y., Shiraishi, Y., Striefler, J. K., Bischoff, S., Lohneis, P., Putter, H., Blau, O., Keilholz, U., Bullinger, L., Pelzer, U., Hummel, M., Riess, H., Ogawa, S., Sinn, M. and Damm, F. (2021). A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. EBioMedicine, 66. AMSTERDAM: ELSEVIER. ISSN 2352-3964